Not registered yet? Please contact our project manager Dr. Mary Gazea . This area is only for members of the research consortium.

News

02 March 2021

Pierre-Emmanuel Rautou is being interviewed by “Science et Vie”

In its March issue, the French journal for laymen on science “Science et Vie” interviewed DECISION coordinator Pierre-Emmanuel Rautou on the topic of multi-omics and the acceleration of biomedicine. By decoding the hidden information at the heart of our cells, multi-omics is revolutionising many areas of research. Click below to read further [Articles in French]:

DANS LE SECRET – DES CELLULES LA MULTIO MIQUE (PDF)

UNE FORMIDABLE ACCÉLÉRATION DE LA BIOMÉDECINE (PDF)

More news

Events

03 September 2021

DECISION Symposium connected to EASL School on Hepatology 2021

Symposium on ‘Management of acute-on-chronic liver failure’

Course director: Prof. Jonel Trebicka

Date: Friday, 03 September 2021

Frankfurt, Germany

More events

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.

Learn more